Health Economics Research Centre, University of Oxford, Oxford, UK.
Syreon Research Institute, Budapest, Hungary.
Per Med. 2023 Jul;20(4):305-319. doi: 10.2217/pme-2022-0145. Epub 2023 Aug 25.
The implementation of adequate financing and reimbursement of personalized medicine (PM) in Europe is still turbulent. The views and experience of stakeholders about barriers in financing and reimbursing PM and potential solutions were elicited and supplemented with literature findings to draft a set of recommendations. Key recommendations to overcome the barriers for adequately financing and reimbursing PM in different healthcare systems in Europe included the provision of legal foundations and establishment of large pan-European databases, use of financial-based agreements and regulation of transparency of prices and reimbursement, and creating a business-friendly environment and attractive market for innovation. The recommendations could be used by health authorities for designing a sequence of policy steps to ensure the timely access to beneficial PM.
在欧洲,实施充足的资金支持和报销政策以推广个性化医学(PM)仍然困难重重。本研究旨在通过调查利益相关者对于在资金支持和报销政策方面存在的障碍的看法和经验,并结合文献发现,为制定一系列建议提供依据。为克服欧洲不同医疗体系中充分为 PM 提供资金支持和报销的障碍,关键建议包括提供法律基础和建立大型泛欧数据库,使用基于财务的协议,规范价格和报销的透明度,并创造有利于创新的商业环境和有吸引力的市场。卫生当局可以利用这些建议来设计一系列政策步骤,以确保及时获得有益的 PM。